155 related articles for article (PubMed ID: 18662789)
1. Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site.
Arcangeli C; Cantale C; Galeffi P; Rosato V
J Struct Biol; 2008 Oct; 164(1):119-33. PubMed ID: 18662789
[TBL] [Abstract][Full Text] [Related]
2. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
3. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains.
Jung S; Spinelli S; Schimmele B; Honegger A; Pugliese L; Cambillau C; Plückthun A
J Mol Biol; 2001 Jun; 309(3):701-16. PubMed ID: 11397090
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the effect of changes in conformation and compactness at the antibody V(L)-V(H) interface upon antigen binding.
Pellequer JL; Chen Sw; Roberts VA; Tainer JA; Getzoff ED
J Mol Recognit; 1999; 12(4):267-75. PubMed ID: 10440998
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of an anti-estradiol antibody by site-directed mutagenesis and molecular modelling: modulation of binding properties and prominent role of the V(L) domain in estradiol recognition.
Coulon S; Pellequer JL; Blachère T; Chartier M; Mappus E; Chen Sw SW; Cuilleron CY; Baty D
J Mol Recognit; 2002; 15(1):6-18. PubMed ID: 11870917
[TBL] [Abstract][Full Text] [Related]
6. The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity.
Masuda K; Sakamoto K; Kojima M; Aburatani T; Ueda T; Ueda H
FEBS J; 2006 May; 273(10):2184-94. PubMed ID: 16649995
[TBL] [Abstract][Full Text] [Related]
7. Knowledge-based design of reagentless fluorescent biosensors from recombinant antibodies.
Renard M; Belkadi L; Hugo N; England P; Altschuh D; Bedouelle H
J Mol Biol; 2002 Apr; 318(2):429-42. PubMed ID: 12051849
[TBL] [Abstract][Full Text] [Related]
8. Expanding the conformational diversity by random insertions to CDRH2 results in improved anti-estradiol antibodies.
Lamminmäki U; Paupério S; Westerlund-Karlsson A; Karvinen J; Virtanen PL; Lövgren T; Saviranta P
J Mol Biol; 1999 Aug; 291(3):589-602. PubMed ID: 10448039
[TBL] [Abstract][Full Text] [Related]
9. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering.
Wörn A; Plückthun A
Biochemistry; 1999 Jul; 38(27):8739-50. PubMed ID: 10393549
[TBL] [Abstract][Full Text] [Related]
10. Engineering antibodies for stability and efficient folding.
Honegger A
Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
[TBL] [Abstract][Full Text] [Related]
11. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
12. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.
Ewert S; Honegger A; Plückthun A
Biochemistry; 2003 Feb; 42(6):1517-28. PubMed ID: 12578364
[TBL] [Abstract][Full Text] [Related]
13. Coevolution of antibody stability and Vκ CDR-L3 canonical structure.
Luo J; Obmolova G; Huang A; Strake B; Teplyakov A; Malia T; Muzammil S; Zhao Y; Gilliland GL; Feng Y
J Mol Biol; 2010 Oct; 402(4):708-19. PubMed ID: 20727359
[TBL] [Abstract][Full Text] [Related]
14. Improving GPX activity of selenium-containing human single-chain Fv antibody by site-directed mutation based on the structural analysis.
Xu J; Song J; Yan F; Chu H; Luo J; Zhao Y; Cheng X; Luo G; Zheng Q; Wei J
J Mol Recognit; 2009; 22(4):293-300. PubMed ID: 19277948
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulation of a high-affinity antibody-protein complex: the binding site is a mosaic of locally flexible and preorganized rigid regions.
Sinha N; Smith-Gill SJ
Cell Biochem Biophys; 2005; 43(2):253-73. PubMed ID: 16049350
[TBL] [Abstract][Full Text] [Related]
16. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms.
Monsellier E; Bedouelle H
J Mol Biol; 2006 Sep; 362(3):580-93. PubMed ID: 16926023
[TBL] [Abstract][Full Text] [Related]
17. The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains.
Honegger A; Plückthun A
J Mol Biol; 2001 Jun; 309(3):687-99. PubMed ID: 11397089
[TBL] [Abstract][Full Text] [Related]
18. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody.
Igawa T; Tsunoda H; Kikuchi Y; Yoshida M; Tanaka M; Koga A; Sekimori Y; Orita T; Aso Y; Hattori K; Tsuchiya M
Protein Eng Des Sel; 2010 Aug; 23(8):667-77. PubMed ID: 20576629
[TBL] [Abstract][Full Text] [Related]
19. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.
Narayanan A; Sellers BD; Jacobson MP
J Mol Biol; 2009 May; 388(5):941-53. PubMed ID: 19324053
[TBL] [Abstract][Full Text] [Related]
20. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.
Kügler M; Stein C; Schwenkert M; Saul D; Vockentanz L; Huber T; Wetzel SK; Scholz O; Plückthun A; Honegger A; Fey GH
Protein Eng Des Sel; 2009 Mar; 22(3):135-47. PubMed ID: 19188138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
